EBG MedAustron GmbH, Marie Curie-Straße 5, A-2700, Wiener Neustadt, Austria.
Department of Radiation Therapy, Medical University of Vienna/AKH Vienna, Vienna, Austria.
Med Phys. 2020 Feb;47(2):380-392. doi: 10.1002/mp.13928. Epub 2019 Dec 29.
This paper describes the clinical implementation and medical commissioning of the MedAustron Particle Therapy Accelerator (MAPTA) for non-isocentric scanned proton beam treatments.
Medical physics involvement during technical commissioning work is presented. Acceptance testing procedures, including advanced measurement methods of intra-spill beam variations, are defined. Beam monitor calibration using two independent methods based on a dose-area product formalism is described. Emphasis is given to the medical commissioning work and the specificities related to non-isocentric irradiation, since a key feature of MedAustron is the routine delivery of non-isocentric scanned proton beam treatments.
Key commissioning results and beam stability trend lines for more than 2 yr of clinical operation have been provided. Intra-spill beam range, size, and position variations were within specifications of 0.3 mm, 15%, and 0.5 mm, respectively. The agreement between two independent beam monitor calibration methods was better than 1.0%. Non-isocentric treatment delivery allowed lateral penumbra reduction of up to about 30%. Daily QA measurements of the beam range, size, position, and dose were always within 1 mm, 10%, 1 mm, and 2% from the baseline data, respectively.
Non-isocentric treatments have been successfully implemented at MedAustron for routine scanned proton beam therapy using horizontal and vertical fixed beamlines. Up to now every patient was treated in non-isocentric conditions. The presented methodology to implement a new Scanned Ion Beam Delivery (SIBD) system into clinical routine for proton therapy may serve as a guidance for other centers.
本文介绍了 MedAustron 粒子治疗加速器(MAPTA)用于非等中心扫描质子束治疗的临床实施和医学调试情况。
介绍了在技术调试工作中医学物理学的参与情况。定义了验收测试程序,包括内溢出束变化的先进测量方法。描述了基于剂量-面积积公式的两种独立方法的束流监视器校准。重点介绍了医学调试工作和与非等中心照射相关的特殊性,因为 MedAustron 的一个关键特点是常规提供非等中心扫描质子束治疗。
提供了超过 2 年临床运行的关键调试结果和束流稳定性趋势线。内溢出束的射程、大小和位置变化分别在 0.3 毫米、15%和 0.5 毫米的规格范围内。两种独立束流监视器校准方法之间的一致性优于 1.0%。非等中心治疗的实施允许横向半影减少高达约 30%。束流射程、大小、位置和剂量的日常质量保证测量值始终在 1 毫米、10%、1 毫米和 2%的基线数据范围内。
MedAustron 已成功实施了使用水平和垂直固定束线的非等中心治疗,用于常规扫描质子束治疗。到目前为止,每位患者都在非等中心条件下接受了治疗。本文介绍的将新的扫描离子束输送(SIBD)系统引入质子治疗临床常规的方法,可以为其他中心提供指导。